Duke logo

ArQule: ARQ 531-101 Ph1 ARQ 531 R/R Hematologic Malignancies - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out what is the best dose of the study drug (ARQ 531) to use in patients with hematologic malignancies.

What is the Condition Being Studied?

Relapsed or Refractory Hematologic Malignancies

Who Can Participate in the Study?

Adults who:
- Have good organ function
- Have a platelet count greater than 50,000/microliters
- Have a creatinine clearance of greater than 60 mL/min
- Have hemoglobin (Hgb) greater than 8.0 g/dL and stable for greater than 1 week

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Give samples of your blood
- Have assessments of your vital signs
- Give urine samples
- Get the study drug, ARQ 531, taken by mouth for one week

Study Details

Full Title
A Phase 1 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects with Relapsed or Refractory Hematologic Malignancies
Principal Investigator
Cell Therapy and Hematologic Malignancies Specialist
Protocol Number
IRB:PRO00101876
NCT:NCT03162536
Phase
Phase I
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698